Accelerating Medicines Partnership - Alzheimer's Disease

The Accelerating Medicines Partnership Alzheimer’s Disease Project (AMP-AD) is a precompetitive partnership among government, industry, and nonprofit organizations that focuses on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets. This multisector partnership is managed by the Foundation for the NIH. The combined funding support for this five-year endeavor is $92.5 million dollars. AMP-AD is comprised of two projects: Project A is supplementing biomarker panels already included in three NIH-funded Phase II/III registration trials in presymptomatic AD through the addition of tau PET imaging and novel fluid biomarkers. Project B integrates analysis of large-scale molecular data from human brain samples with network modeling approaches and experimental validation, and enables rapid, broad sharing of data and analytical tools.

Read the NIA’s description of the program here. To learn about the AMP Type 2 Diabetes Project click here, the AMP RA/SLE Project click here or the AMP Parkinson's Disease Project click here.


Results & Accomplishments

Scientific Publications

Global quantitive analysis of human brain proteome in Alzheimer's and Parkinson's Disease. Lingyan Ping, Duc M. Duong, Luming Yin, Marla Gearing, James J. Lah et al. Scientific Data 5:180036 doi: 10.1038/sdata.2018.36 (2018).  


Nature Reviews Drug Discovery (February 27, 2019): Massive NIH-industry project opens portals to target validation


AbbVie Inc.
Alliance for Aging Research
Alzheimer's Association
Alzheimer’s Drug Discovery Foundation
Eli Lilly and Company
The Geoffrey Beene Foundation Alzheimer's Initiative
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
U.S. Food and Drug Administration (FDA)
Vradenburg Foundation


Rosa Canet-Aviles, Ph.D., Scientific Program Manager, Neuroscience,